303 Phase II trial of neoadjuvant nivolumab (Nivo) and intra-tumoral (IT) CMP-001 in high-risk resectable melanoma (Neo-C-Nivo): final results

• Hassane Zarour,
• John Kirkwood,
• Joe-Marc Chauvin,
• Arivarasan Karunamurthy,
• Douglas Hartman,
• Richelle DeBlasio,
• Quanquan Ding,
• Ornella Pagliano,
• Amy Rose

Affiliations

Hassane Zarour

Aff13 grid.21925.3d0000000419369000University of Pittsburgh Pittsburgh PA USA

John Kirkwood

16University of Pittsburgh Medical Center, Pittsburgh, PA, USA

Joe-Marc Chauvin

Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

Arivarasan Karunamurthy

2University of Pittsburgh, Pittsburgh, PA, USA

Douglas Hartman

2University of Pittsburgh, Pittsburgh, PA, USA

Richelle DeBlasio

1Hillman Cancer Center, Pittsburgh, PA, USA

Quanquan Ding

1Hillman Cancer Center, Pittsburgh, PA, USA

Ornella Pagliano

1Hillman Cancer Center, Pittsburgh, PA, USA

Amy Rose

1Hillman Cancer Center, Pittsburgh, PA, USA